Clinical Trial Update: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in metastatic colorectal cancer previously treated with fluoropyrimidine, oxalipla…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• ABT-165
• Bevacizumab (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)

Snippet

Sponsor: AbbVie | Conditions: Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-02-09